Following a positive H1 pre-close update yesterday, Symphony has announced that it has received U.S. Food and Drug Administration (FDA) approval for a much greater loading and wider use of its d2p antimicrobial technology for bread-packaging. This augments a narrow approval received from the FDA in February 2020. The enhanced approval will open-up use of the technology to a wider range of customers and products. Management state that they are confident that commercial sales will commence this ye ....
14 Jul 2021
Symphony Environmental (SYM LN) - Further FDA approval for d2p
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Symphony Environmental (SYM LN) - Further FDA approval for d2p
Symphony Environmental Technologies plc (SYM:LON) | 3.2 0 0.0% | Mkt Cap: 6.01m
- Published:
14 Jul 2021 -
Author:
Robin Byde -
Pages:
6
Following a positive H1 pre-close update yesterday, Symphony has announced that it has received U.S. Food and Drug Administration (FDA) approval for a much greater loading and wider use of its d2p antimicrobial technology for bread-packaging. This augments a narrow approval received from the FDA in February 2020. The enhanced approval will open-up use of the technology to a wider range of customers and products. Management state that they are confident that commercial sales will commence this ye ....